13.10.2015 • News

Teva Launches Generic Dutasteride

Israeli generics giant Teva Pharmaceutical Industries has launched a generic equivalent to Glaxo SmithKline’s Avodart (dutasteride) 0.5 mg capsules on the US market.

The active ingredient dutasteride, a 5 alpha-reductase enzyme inhibitor, works by lowering production of the hormone dihydrotestosterone (DHT and is used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

First drugmaker to file for a generic application, Teva said it expects its product to be exclusive for several weeks. GlaxoSmithKline has annual sales of about $467 million from the capsules.

 

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.